Shunned By Sentiment, Supported by Science

I look for situations where the risk-reward is skewed heavily in one direction. Amgen (AMGN) just set up that exact scenario with their Q3 earnings.

Strong revenue growth, broad product momentum, attractive valuation, and a market that’s already priced in the worst-case scenario. When you find quality trading cheaply because of overblown fears, you’ve found an opportunity.

Amgen reported 12% year-over-year revenue growth in Q3, with product sales right in step.

That acceleration from last quarter’s 9% is impressive, especially in a sector under constant pressure from both Washington and Wall Street.

Beating estimates by nearly $600 million is a reminder that this company knows how to hit its marks.

Repatha posted 40% sales growth. Ordinarily, that kind of performance would grab headlines.

But instead of basking in the glow, Amgen made a smart, calculated move: it slashed Repatha’s price by 60% through its AmgenNow platform.

This was clearly a preemptive maneuver to maintain pricing power before the government tries to do it for them. Margins take a hit now, but the strategic advantage could last for years.

Tezspire isn’t just hanging around either. Sales jumped 40% this quarter, and it landed FDA approval for chronic rhinosinusitis with nasal polyps, expanding its use beyond severe asthma.

That opens up a higher-volume, underserved market. It’s not a headline-grabber yet, but that could change as this indication gains traction.

Margins dipped, with the operating margin declining by 2.5 percentage points, but let’s not pretend this is mismanagement.

Cost of sales rose, and R&D spend increased. But this is productive R&D. The pipeline is crowded with late-stage programs, and Amgen has shown over and over again that it knows how to commercialize.

EPS rose just 1%, but still beat by $0.63. Management responded by raising full-year guidance on both the top and bottom lines.

Yes, revenue growth is expected to slow from 19% in 2024 to 8% in 2025, but earnings growth is holding steady at 6%. That’s improved operational leverage in action.

SG&A fell as a percentage of sales. Capex guidance was nudged lower. That tells you management is keeping a sharp eye on costs and is positioning for stronger free cash flow.

That cash is going to be useful – whether it’s buying back stock, hiking dividends, or adding strategic assets to the pipeline.

Yet, Amgen is still being treated like a laggard. It’s trading well below the healthcare sector’s median forward P/E.

This is a company growing faster than its peers, with a deeper pipeline, and it’s still being priced like it’s standing still. It isn’t.

The technical picture is supportive. The stock is nearing six-month highs. RSI and momentum are strong, but not stretched. There’s no real sign of overbought excess or profit-taking.

Institutions are likely accumulating quietly, and that aligns perfectly with what the fundamentals are telling us.

Amgen doesn’t need a rebrand. It doesn’t need to chase buzz. It just needs time to do what it’s always done – turn good science into reliable returns.

That process is already underway, whether the market appreciates it yet or not.

This is the kind of name that sits in your portfolio and does the heavy lifting. It’s a leader with discipline, visibility, and upside that’s been underappreciated in the current tape.

There’s no need to rush in, but there’s every reason to start building a position if you haven’t already.

If you’re managing real capital and looking for a name that can quietly compound while the market cycles through noise, this is your setup.

Solid fundamentals, conservative guidance, and enough inefficiency in the pricing to give you a margin of safety.

When the odds are this lopsided, you shouldn’t sit back and wait for confirmation. You should step in.

Because when the market wakes up, it won’t leave the lights on for you – it’ll already be gone with your seat.